Cargando…
The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer
Anaplastic thyroid cancer represents 1%–2% of thyroid cancers. For its aggressiveness, it is considered a systemic disease at the time of diagnosis. Surgery remains the cornerstone of therapy in resectable tumor. Traditional chemotherapy has little effect on metastatic disease. A multimodality appro...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3787923/ https://www.ncbi.nlm.nih.gov/pubmed/24092989 http://dx.doi.org/10.2147/OTT.S46545 |
_version_ | 1782286248802516992 |
---|---|
author | Denaro, Nerina Nigro, Cristiana Lo Russi, Elvio G Merlano, Marco C |
author_facet | Denaro, Nerina Nigro, Cristiana Lo Russi, Elvio G Merlano, Marco C |
author_sort | Denaro, Nerina |
collection | PubMed |
description | Anaplastic thyroid cancer represents 1%–2% of thyroid cancers. For its aggressiveness, it is considered a systemic disease at the time of diagnosis. Surgery remains the cornerstone of therapy in resectable tumor. Traditional chemotherapy has little effect on metastatic disease. A multimodality approach, incorporating cytoreductive surgical resection, chemoradiation, either concurrently or sequentially, and new promising target therapies is advisable. Doxorubicin is the most commonly used agent, with a response rate of 22%. Recently, other chemotherapy agents have been used, such as paclitaxel and gemcitabine, with superimposable activity and response rates of 10%–20%. However, survival of patients with anaplastic thyroid cancer has changed little in the past 50 years, despite more aggressive systemic and radiotherapies. Several new agents are currently under investigation. Some of them, such as sorafenib, imatinib, and axitinib have been tested in small clinical trials, showing promising disease control rates ranging from 35%–75%. Referral of patients for participation in clinical trials is needed. |
format | Online Article Text |
id | pubmed-3787923 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-37879232013-10-03 The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer Denaro, Nerina Nigro, Cristiana Lo Russi, Elvio G Merlano, Marco C Onco Targets Ther Review Anaplastic thyroid cancer represents 1%–2% of thyroid cancers. For its aggressiveness, it is considered a systemic disease at the time of diagnosis. Surgery remains the cornerstone of therapy in resectable tumor. Traditional chemotherapy has little effect on metastatic disease. A multimodality approach, incorporating cytoreductive surgical resection, chemoradiation, either concurrently or sequentially, and new promising target therapies is advisable. Doxorubicin is the most commonly used agent, with a response rate of 22%. Recently, other chemotherapy agents have been used, such as paclitaxel and gemcitabine, with superimposable activity and response rates of 10%–20%. However, survival of patients with anaplastic thyroid cancer has changed little in the past 50 years, despite more aggressive systemic and radiotherapies. Several new agents are currently under investigation. Some of them, such as sorafenib, imatinib, and axitinib have been tested in small clinical trials, showing promising disease control rates ranging from 35%–75%. Referral of patients for participation in clinical trials is needed. Dove Medical Press 2013-09-16 /pmc/articles/PMC3787923/ /pubmed/24092989 http://dx.doi.org/10.2147/OTT.S46545 Text en © 2013 Denaro et al, This work is published by Dove Medical Press Ltd, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Ltd, provided the work is properly attributed. |
spellingShingle | Review Denaro, Nerina Nigro, Cristiana Lo Russi, Elvio G Merlano, Marco C The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer |
title | The role of chemotherapy and latest emerging target therapies in anaplastic thyroid
cancer |
title_full | The role of chemotherapy and latest emerging target therapies in anaplastic thyroid
cancer |
title_fullStr | The role of chemotherapy and latest emerging target therapies in anaplastic thyroid
cancer |
title_full_unstemmed | The role of chemotherapy and latest emerging target therapies in anaplastic thyroid
cancer |
title_short | The role of chemotherapy and latest emerging target therapies in anaplastic thyroid
cancer |
title_sort | role of chemotherapy and latest emerging target therapies in anaplastic thyroid
cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3787923/ https://www.ncbi.nlm.nih.gov/pubmed/24092989 http://dx.doi.org/10.2147/OTT.S46545 |
work_keys_str_mv | AT denaronerina theroleofchemotherapyandlatestemergingtargettherapiesinanaplasticthyroidcancer AT nigrocristianalo theroleofchemotherapyandlatestemergingtargettherapiesinanaplasticthyroidcancer AT russielviog theroleofchemotherapyandlatestemergingtargettherapiesinanaplasticthyroidcancer AT merlanomarcoc theroleofchemotherapyandlatestemergingtargettherapiesinanaplasticthyroidcancer AT denaronerina roleofchemotherapyandlatestemergingtargettherapiesinanaplasticthyroidcancer AT nigrocristianalo roleofchemotherapyandlatestemergingtargettherapiesinanaplasticthyroidcancer AT russielviog roleofchemotherapyandlatestemergingtargettherapiesinanaplasticthyroidcancer AT merlanomarcoc roleofchemotherapyandlatestemergingtargettherapiesinanaplasticthyroidcancer |